Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2784952 | 0.89 | SLC22A6 (0.39) | ALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL9652062 | 0.89 | ALDH1A1 (0.50) | ALDH1A1TSHRTDP1 | |
| SCHEMBL2784955 | 0.89 | SLC22A6 (0.39) | ALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL20232410 | 0.85 | — | — | |
| SCHEMBL3381726 | 0.85 | — | — | |
| SCHEMBL839656 | 0.85 | — | — | |
| SCHEMBL9724921 | 0.85 | — | — | |
| SCHEMBL7980233 | 0.83 | — | — | |
| SCHEMBL27946985 | 0.83 | — | — | |
| SCHEMBL7710987 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4306524-A2 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | PureTech LYT, Inc. (US) | 2024-01-17 | — | — | EP | disclosed |
| CN-117122721-A | Sponge | 贵州省农作物品种资源研究所 | 2023-11-28 | — | — | CN | disclosed |
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20210300962-A1 | LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2021159021-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | PURETECH LYT, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-20200390777-A1 | LIPID PRODRUGS OF MYCOPHENOLIC ACID AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2020028787-A1 | LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF | PureTech Health LLC (US) | 2020-02-06 | — | — | WO | disclosed |
| CN-105669970-B | Polyamide-based expandable flame retardant carbon forming agent and its preparation method and application of the main chain containing piperazine structure | 四川大学 | 2018-11-02 | — | — | CN | disclosed |
| US-5039773-A | Toner and developer compositions with thermotropic liquid crystalline polymers | XEROX CORPORATION (US) | 1991-08-13 | — | — | US | disclosed |
| US-4891293-A | Toner and developer compositions with thermotropic liquid crystalline polymers | XEROX CORPORATION (US) | 1990-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338552-A1 | LIPID PRODRUGS OF NEUROSTEROIDS | CYP21A2, CYP46A1, CYP17A1 | ALDH1A1 1218/4885TSHR 1372/4885TDP1 1452/4885 |
| US-20200390777-A1 | LIPID PRODRUGS OF MYCOPHENOLIC ACID AND USES THEREOF | MALT1, CYP2B6, LIPA | ALDH1A1 959/4885TSHR 2734/4885TDP1 1969/4885 |
| US-20210300962-A1 | LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF | CYP21A2, CYP46A1, CYP17A1 | ALDH1A1 1430/4885TSHR 1457/4885TDP1 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.